Preclinical evidence suggests that type I IFN-stimulated cross-priming of DC against tumour-associated antigen is crucial for cancer immunosurveillance and can be used to effectively increase anti-tumour CD8+ T-cell responses (5). This evidence concerns the gene CD8A and neoplasm.